Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,331,078
-
Total 13F shares
-
9,948,182
-
Share change
-
-128,251
-
Total reported value
-
$31,335,126
-
Price per share
-
$3.15
-
Number of holders
-
39
-
Value change
-
-$1,135,510
-
Number of buys
-
15
-
Number of sells
-
11
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2017
As of 30 Jun 2017,
Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,948,182 shares.
The largest 10 holders included
BVF INC/IL, Capital World Investors, PERCEPTIVE ADVISORS LLC, ORBIMED ADVISORS LLC, Alyeska Investment Group, L.P., DAFNA Capital Management LLC, Invesco Private Capital, Inc., Tekla Capital Management LLC, SABBY MANAGEMENT, LLC, and Point72 Asset Management, L.P..
This page lists
39
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.